Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.
作者信息
Taylor Shawn R, Moody Michayla T
机构信息
Wingate University, Hendersonville Campus, Hendersonville, NC, USA.
Dale Fell Health Center, Appalachian Mountain Community Health Center, Asheville, NC, USA.
出版信息
J Pharm Technol. 2018 Oct;34(5):231-232. doi: 10.1177/8755122518782155. Epub 2018 Jun 25.
Abstract
摘要
相似文献
1
Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.
J Pharm Technol. 2018 Oct;34(5):231-232. doi: 10.1177/8755122518782155. Epub 2018 Jun 25.
2
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.
3
Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.
Diabetes Res Clin Pract. 2019 Oct;156:107820. doi: 10.1016/j.diabres.2019.107820. Epub 2019 Aug 22.
4
Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Diabetes Ther. 2021 May;12(5):1535-1551. doi: 10.1007/s13300-021-01039-5. Epub 2021 Apr 16.
5
Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
Endocr J. 2017 Feb 27;64(2):191-206. doi: 10.1507/endocrj.EJ16-0365. Epub 2016 Nov 15.
6
Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.
Diabetes Ther. 2019 Aug;10(4):1453-1463. doi: 10.1007/s13300-019-0658-7. Epub 2019 Jun 25.
7
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Diabetes Care. 2017 May;40(5):647-654. doi: 10.2337/dc16-0984. Epub 2017 Mar 10.
8
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
Diabetes Ther. 2020 Aug;11(8):1627-1638. doi: 10.1007/s13300-020-00863-5. Epub 2020 Jun 20.
9
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Diabetes Ther. 2021 May;12(5):1553-1567. doi: 10.1007/s13300-021-01055-5. Epub 2021 Apr 17.
10
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
Diabetologia. 2020 Nov;63(11):2434-2445. doi: 10.1007/s00125-020-05265-7. Epub 2020 Aug 31.
引用本文的文献
1
Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.
Front Endocrinol (Lausanne). 2025 Aug 26;16:1486655. doi: 10.3389/fendo.2025.1486655. eCollection 2025.
2
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.
Medicina (Kaunas). 2024 Dec 26;61(1):17. doi: 10.3390/medicina61010017.
3
Semaglutide-associated kidney injury.
Clin Kidney J. 2024 Aug 13;17(9):sfae250. doi: 10.1093/ckj/sfae250. eCollection 2024 Sep.
4
Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Front Endocrinol (Lausanne). 2022 Dec 13;13:1032199. doi: 10.3389/fendo.2022.1032199. eCollection 2022.
5
A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist.
Clin Diabetes. 2022 Fall;40(4):508-510. doi: 10.2337/cd21-0142.
本文引用的文献
1
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.
2
Acute tubulointerstitial nephritis following treatment with exenatide.
Diabet Med. 2013 Jan;30(1):123-5. doi: 10.1111/j.1464-5491.2012.03738.x.
3
Liraglutide-induced acute kidney injury.
Pharmacotherapy. 2012 Jan;32(1):e7-11. doi: 10.1002/PHAR.1014.
4
Exenatide-associated ischemic renal failure.
Diabetes Care. 2009 Feb;32(2):e22-3. doi: 10.2337/dc08-1309.
5
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件